Skip to main navigation Skip to search Skip to main content

Dietary restriction reprograms CD8+ T cell fate to enhance anti-tumour immunity and immunotherapy responses

  • Brandon M. Oswald
  • , Lisa M. DeCamp
  • , Joseph Longo
  • , Michael S. Dahabieh
  • , Nicholas Bunda
  • , Benjamin K. Johnson
  • , McLane J. Watson
  • , Shixin Ma
  • , Samuel E.J. Preston
  • , Ryan D. Sheldon
  • , Michael P. Vincent
  • , Abigail E. Ellis
  • , Molly T. Soper-Hopper
  • , Christine Isaguirre
  • , Dahlya Kamarudin
  • , Hui Shen
  • , Kelsey S. Williams
  • , Peter A. Crawford
  • , Susan Kaech
  • , H. Josh Jang
  • Evan C. Lien, Connie M. Krawczyk, Russell G. Jones

Research output: Contribution to journalArticlepeer-review

Abstract

Reducing calorie intake through dietary restriction (DR) slows tumour growth in mammals, yet the underlying mechanisms are poorly defined. Here, we show that DR enhances anti-tumour immunity by optimizing CD8+ T cell function within the tumour microenvironment (TME). Using syngeneic xenograft tumour models, we found that DR induces a profound reprogramming of CD8+ T cell fate in the TME, favouring the expansion of effector T cell subsets with enhanced metabolic capacity and cytotoxic potential, while limiting the accumulation of terminally exhausted T cells. This metabolic reprogramming is driven by enhanced ketone body oxidation, particularly β-hydroxybutyrate (βOHB), which is elevated in both the circulation and tumour tissues of DR-fed mice. βOHB fuels T cell oxidative metabolism under DR, increasing mitochondrial membrane potential and tricarboxylic acid cycle-dependent pathways critical for T cell effector function, including acetyl-CoA production. By contrast, T cells deficient for ketone body oxidation exhibit reduced mitochondrial function, increased exhaustion and fail to control tumour growth under DR conditions. Importantly, DR synergizes with anti-PD1 immunotherapy, further augmenting anti-tumour T cell responses and limiting tumour progression. Our findings reveal that T cell metabolic reprogramming is central to the anti-tumour effects of DR, highlighting nutritional control of CD8+ T cell fate as a key driver of anti-tumour immunity.

Original languageEnglish (US)
Pages (from-to)2489-2509
Number of pages21
JournalNature Metabolism
Volume7
Issue number12
DOIs
StatePublished - Dec 2025

Bibliographical note

Publisher Copyright:
© The Author(s) 2025.

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Dietary restriction reprograms CD8+ T cell fate to enhance anti-tumour immunity and immunotherapy responses'. Together they form a unique fingerprint.

Cite this